Market Size
The Global Digital Therapeutics for Neurological Disorders Market reached US$ 267.43 million in 2025 and is expected to reach US$ 507.95 million by 2035, growing at a CAGR of 8.3% during the forecast period (2026–2035).
Digital therapeutics for neurological disorders refer to evidence-based therapeutic interventions that leverage digital platforms such as mobile apps, software programs, virtual reality (VR), wearables and other connected devices to prevent, manage or treat neurological conditions. These treatments are often powered by advanced technologies such as artificial intelligence (AI), machine learning (ML), big data analytics and neurostimulation to deliver tailored, real-time and often non-invasive care.
Digital therapeutics are designed to provide precise, personalized and patient-centered interventions, focusing on cognitive, motor and behavioral functions that are impacted by neurological disorders. They can be used in conjunction with traditional treatments or as standalone therapies and may involve self-management, rehabilitation, symptom monitoring or behavior modification. These digital solutions aim to improve clinical outcomes while offering greater accessibility, convenience and reduced costs compared to traditional treatments.
Key Takeaways
- The market is projected to nearly double from US$ 267.43 million in 2025 to US$ 507.95 million by 2035, highlighting sustained investment opportunities in digital neurological care.
- Home-based treatment models and remote patient monitoring are accelerating adoption across chronic neurological diseases.
- Software therapeutics remain the leading product category due to their accessibility, affordability, and ability to support continuous patient engagement.
- North America maintains market leadership through supportive FDA regulatory pathways, advanced healthcare infrastructure, and high neurological disease prevalence.
- AI, machine learning, wearable integration, and personalized digital interventions are improving clinical outcomes while reducing healthcare costs.
- Increasing cybersecurity risks and patient data privacy concerns remain important challenges influencing technology adoption and regulatory compliance.
- Strategic investments in prescription digital therapeutics, cognitive assessment platforms, and virtual rehabilitation technologies continue to reshape the competitive landscape.
Market Scope
| Metrics | Details |
| Market Size (2025) | US$ 267.43 Million |
| Forecast Market Size (2035) | US$ 507.95 Million |
| CAGR (2026-2035) | 8.30% |
| Historic Years | 2023-2024 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Product Type | Software Therapeutics, Wearable Devices |
| Disease Type | Neurodegenerative Disorders, Mental Health Disorders, Stroke & Cerebrovascular Disorders, Sleep Disorders, Cognitive Disorders, Others |
| End Users | Hospitals, Specialty Clinics, Neuro-Rehabilitation Centers, Homecare Settings, Others |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, Middle East & Africa |
| Leading Region | North America |
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
Shift Towards Home-Based Care & Remote Patient Monitoring
The shift towards home-based care & remote patient monitoring is significantly driving the growth of the digital therapeutics for neurological disorders market and is expected to drive the market over the forecast period. Home-based care allows patients to receive treatment without the need for frequent hospital visits, particularly important for patients with chronic neurological conditions like Parkinson's Disease, Alzheimer's or Multiple Sclerosis. By leveraging digital therapeutics, patients can manage their symptoms at home using mobile apps, wearables or other digital platforms.
For instance, Akili Interactive's EndeavorRx, a digital therapeutic for ADHD, is an example of a solution that can be used at home, allowing patients to receive therapy without the need for in-clinic visits, reducing the burden on both patients and healthcare providers.
Remote patient monitoring helps overcome geographic barriers, allowing patients in rural or underserved areas to access advanced neurological care without traveling long distances. Digital therapeutics solutions, which include apps for symptom tracking and therapy adherence, can be used anywhere, bridging gaps in access to specialized care.
Digital therapeutics are designed to engage patients by offering tools like self-management apps, reminders, and personalized interventions. This improves patient adherence to therapy regimens, especially in chronic neurological conditions that require long-term management. The interactive and gamified nature of many digital solutions boosts engagement, making it easier for patients to stick with prescribed therapy regimens and track their progress regularly.
Data Privacy & Cybersecurity Concerns
Data privacy and cybersecurity are major concerns in the digital therapeutics for neurological disorders market, as these platforms rely on the collection, storage and analysis of sensitive patient data, including personal health information (PHI), cognitive assessments, and real-time health monitoring. Digital therapeutics platforms often store patient data in cloud-based systems or other online infrastructures, making them vulnerable to cyberattacks. A breach of sensitive health data could result in identity theft, financial fraud, or even medical fraud.
For instance, according to the HIPAA Journal, in August 2023, 23 million breached healthcare records are noticed. Over the past 12 months, an average of 9,989,003 healthcare records were breached each month. In the year to August 31, 2024, there have been 491 data breaches of 500 or more records, and at least 58,668,002 records are known to have been breached. The average breach size in 2024 is currently 119,487 records and the median breach size is 4,109 records.
Market Segmentation Analysis
The global digital therapeutics for neurological disorders market is segmented based on product type, disease type, end-user and region.
Product Type:
The software therapeutics from the product type segment are expected to dominate the global digital therapeutics for neurological disorders market
Software therapeutics, primarily through mobile applications and web-based platforms, are accessible anytime, anywhere, making them a convenient option for patients. This ease of use is a major reason why software-based digital therapeutics are preferred in home-based care scenarios, especially for neurological conditions where ongoing management is required.
For instance, Cogstate’s Cognigram is a software platform that provides cognitive testing for people with Alzheimer’s disease and mild cognitive impairment. This platform enables patients to track cognitive performance remotely and interact with their healthcare provider, offering a more convenient and accessible solution than traditional in-clinic testing.
Software therapeutics are generally more cost-effective compared to traditional treatments that involve frequent doctor visits, hospitalizations, or long-term medication. By offering at-home solutions and reducing the need for in-person consultations, software therapeutics can lower the overall healthcare costs for both patients and healthcare providers. For instance, Pear Therapeutics’ reSET-O, a prescription digital therapeutic for opioid use disorder, is an FDA-approved software solution that reduces the need for continuous in-person visits and provides remote support.
Market Geographical Analysis
North America is expected to hold a significant position in the global digital therapeutics for neurological disorders market
North America, and particularly the United States, benefits from a well-established regulatory framework through the FDA (Food and Drug Administration), which has streamlined the approval process for digital therapeutics. This regulatory clarity boosts market confidence and accelerates the adoption of digital therapeutics solutions for neurological disorders. For instance, The FDA’s Digital Health Innovation Action Plan aims to promote innovation and expedite the approval of digital therapeutics. The approval of products like EndeavorRx (for ADHD) and reSET (for addiction treatment) demonstrates the regulatory readiness in North America to approve digital solutions for treating neurological conditions.
The prevalence of neurological disorders such as Alzheimer's disease, Parkinson’s disease, multiple sclerosis, and epilepsy is rising in North America, driving the demand for digital therapeutics. The aging population in the United States and Canada is a major factor contributing to this increase. The number of people diagnosed with Alzheimer’s is expected to grow significantly in North America due to the aging Baby Boomer population.
Digital therapeutic platforms that provide cognitive training, symptom tracking, and remote monitoring are increasingly sought after to manage the long-term care needs of these patients. For instance, according to the Alzheimer’s Association, in the U.S. alone, 5.8 million people were living with Alzheimer's disease in 2020, and that number is expected to double by 2060. As the number of patients increases, so does the demand for digital health solutions to manage these conditions.
Major Global Players
The major global players in the digital therapeutics for neurological disorders market include Akili, Inc., Click Therapeutics, Inc., BigHealth, Apple Inc., MindMaze Inc, NeuroPace, Inc., NeurologyToolKit, Matoph Labs e.U., Fullpower Technologies, Inc., Neybox Digital Ltd. and among others.
Recent Developments
In May 2026, Pear Therapeutics (revived platform assets via partners) expanded digital therapeutics solutions targeting neurological conditions such as substance use and insomnia. The initiative focuses on AI-driven, evidence-based interventions. This supports personalized neuro care.
In April 2026, Akili Interactive advanced its FDA-cleared digital therapeutic platform for ADHD and cognitive disorders with new clinical data. The development enhances treatment efficacy and patient engagement. This benefits neurological care.
In March 2026, Click Therapeutics strengthened its pipeline with digital therapeutics for neurological and psychiatric disorders. The innovation focuses on prescription-based software treatments. This supports scalable digital healthcare.
Why Purchase the Report?
- Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
- Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
- Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
- Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
- Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
- Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
- Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
- Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
- Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
- Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
- Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
- Post-market Surveillance: Uses post-market data to enhance product safety and access.
- Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
Market Impact Assessment
Increasing regulatory acceptance of digital therapeutics, combined with growing healthcare digitization and AI adoption, continues to accelerate commercialization opportunities. At the same time, cybersecurity investment has become a strategic requirement as healthcare organizations seek to protect sensitive neurological patient data while complying with evolving privacy regulations.
The market is expected to benefit from continued advancements in cloud computing, wearable technologies, machine learning, and personalized treatment algorithms, although maintaining patient trust through robust cybersecurity practices will remain essential.
Report Benefits
This report provides valuable insights for:
- Pharmaceutical and biotechnology companies evaluating digital therapeutic partnerships.
- Medical device manufacturers developing connected neurological solutions.
- Investors assessing emerging digital health opportunities.
- Healthcare providers implementing remote neurological care programs.
- Technology companies building AI-enabled healthcare platforms.
- Strategy teams evaluating competitive positioning and expansion opportunities.
- Procurement professionals identifying scalable digital treatment solutions.
- Market access and commercialization teams monitoring reimbursement and regulatory developments.
Target Audience
- Pharmaceutical Companies
- Biotechnology Companies
- Medical Device Manufacturers
- Digital Therapeutics Developers
- Hospitals and Health Systems
- Specialty Neurology Clinics
- Neuro-Rehabilitation Centers
- Home Healthcare Providers
- AI and Digital Health Companies
- Healthcare Investors and Venture Capital Firms
- Regulatory Authorities
- Healthcare Consultants
- Market Research Organizations
- Academic and Clinical Research Institutions
- Distribution and Supply Chain Managers
Conclusion
The digital therapeutics for neurological disorders market is steadily progressing toward becoming an integral component of neurological disease management. Growing demand for home-based care, expanding regulatory support, advances in artificial intelligence, and increased patient acceptance of software-driven therapies are creating favorable commercial conditions across the healthcare ecosystem.
Organizations capable of delivering clinically validated, secure, and personalized digital therapeutic platforms will be well positioned to capitalize on future growth. While cybersecurity and data privacy remain important operational challenges, continued innovation in prescription digital therapeutics, remote monitoring, and cognitive rehabilitation is expected to support sustained market expansion through 2035, making this sector an attractive opportunity for healthcare providers, technology companies, investors, and strategic decision-makers.
